138 related articles for article (PubMed ID: 11886377)
1. Class III receptor tyrosine kinases: role in leukaemogenesis.
Reilly JT
Br J Haematol; 2002 Mar; 116(4):744-57. PubMed ID: 11886377
[No Abstract] [Full Text] [Related]
2. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand.
McClanahan T; Culpepper J; Campbell D; Wagner J; Franz-Bacon K; Mattson J; Tsai S; Luh J; Guimaraes MJ; Mattei MG; Rosnet O; Birnbaum D; Hannum CH
Blood; 1996 Nov; 88(9):3371-82. PubMed ID: 8896402
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia.
Abu-Duhier FM; Goodeve AC; Wilson GA; Care RS; Peake IR; Reilly JT
Br J Haematol; 2001 Jun; 113(4):983-8. PubMed ID: 11442493
[TBL] [Abstract][Full Text] [Related]
5. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Pandey A; Volkots DL; Seroogy JM; Rose JW; Yu JC; Lambing JL; Hutchaleelaha A; Hollenbach SJ; Abe K; Giese NA; Scarborough RM
J Med Chem; 2002 Aug; 45(17):3772-93. PubMed ID: 12166950
[TBL] [Abstract][Full Text] [Related]
6. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.
Paietta E; Ferrando AA; Neuberg D; Bennett JM; Racevskis J; Lazarus H; Dewald G; Rowe JM; Wiernik PH; Tallman MS; Look AT
Blood; 2004 Jul; 104(2):558-60. PubMed ID: 15044257
[TBL] [Abstract][Full Text] [Related]
7. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease.
Pardanani A; Reeder TL; Kimlinger TK; Baek JY; Li CY; Butterfield JH; Tefferi A
Leuk Res; 2003 Aug; 27(8):739-42. PubMed ID: 12801532
[TBL] [Abstract][Full Text] [Related]
8. RTK SLAP down: the emerging role of Src-like adaptor protein as a key player in receptor tyrosine kinase signaling.
Wybenga-Groot LE; McGlade CJ
Cell Signal; 2015 Feb; 27(2):267-74. PubMed ID: 25446260
[TBL] [Abstract][Full Text] [Related]
9. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Taylor JR; Brownlow N; Domin J; Dibb NJ
Oncogene; 2006 Jan; 25(1):147-51. PubMed ID: 16170366
[TBL] [Abstract][Full Text] [Related]
10. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val.
Sperr WR; Walchshofer S; Horny HP; Födinger M; Simonitsch I; Fritsche-Polanz R; Schwarzinger I; Tschachler E; Sillaber C; Hagen W; Geissler K; Chott A; Lechner K; Valent P
Br J Haematol; 1998 Dec; 103(3):740-9. PubMed ID: 9858225
[TBL] [Abstract][Full Text] [Related]
11. Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.
Sabattini S; Barzon G; Giantin M; Lopparelli RM; Dacasto M; Prata D; Bettini G
Vet Comp Oncol; 2017 Sep; 15(3):1051-1061. PubMed ID: 27278268
[TBL] [Abstract][Full Text] [Related]
12. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
[TBL] [Abstract][Full Text] [Related]
13. Genomic structure of human FLT3: implications for mutational analysis.
Abu-Duhier FM; Goodeve AC; Wilson GA; Care RS; Peake IR; Reilly JT
Br J Haematol; 2001 Jun; 113(4):1076-7. PubMed ID: 11442505
[No Abstract] [Full Text] [Related]
14. Point mutations in the FLT3 gene in AML.
Griffin JD
Blood; 2001 Apr; 97(8):2193A-2193. PubMed ID: 11290575
[No Abstract] [Full Text] [Related]
15. Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase.
Rottapel R; Turck CW; Casteran N; Liu X; Birnbaum D; Pawson T; Dubreuil P
Oncogene; 1994 Jun; 9(6):1755-65. PubMed ID: 8183574
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling.
Torrent M; Rickert K; Pan BS; Sepp-Lorenzino L
J Mol Graph Model; 2004 Oct; 23(2):153-65. PubMed ID: 15363457
[TBL] [Abstract][Full Text] [Related]
17. Flt3 mutations and leukaemia.
Kottaridis PD; Gale RE; Linch DC
Br J Haematol; 2003 Aug; 122(4):523-38. PubMed ID: 12899708
[No Abstract] [Full Text] [Related]
18. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic potential of the c-FMS proto-oncogene (CSF-1 receptor).
Roussel MF; Sherr CJ
Cell Cycle; 2003; 2(1):5-6. PubMed ID: 12695672
[No Abstract] [Full Text] [Related]
20. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
